Introduction
Kidney cancer is not a single disease; it comprises a number of different cancers that occur in the kidney, each with a differ ent histology and clinical course, which respond differently to therapy and are caused by mutations in different genes.
1 the study of hereditary kidney cancer syndromes has led to the identification of genes implicated in familial clear cell renal carcinoma, familial chromophobe kidney cancer, familial type 1 and type 2 papillary kidney cancer, familial nonsyndromic renal carcinoma and tuberous sclerosis complex. all cancer is essentially genetic 2 and several investigators have recently highlighted the central importance of metabolic pathways in cancer.
3-5 each of the kidney cancer genes identified so far interact with cell metabolism pathways involved in energy, nutrient, iron or oxygen sensing (Figure 1 ).
Hypoxia-inducible factors (HiFs) are oxygen-sensitive basic helix-loop-helix transcription factors, which regulate biological processes that facilitate both oxygen delivery and cellular adaptation to oxygen deprivation. HiF-α, together with the constitutively expressed HiF-β subunit, bind to hypoxia-response elements in gene promoters to regulate the expression of genes that are involved in energy metab olism, angiogenesis, erythropoiesis, iron metab olism, cell proliferation, apoptosis and other bio logical processes. HiF1-α and HiF2-α mediate transcription of a number of downstream genes thought to be important in cancer including transforming growth factor alpha (TGFA), platelet-derived growth factor (PDGF), and vascular endothelial growth factor (VEGF). we propose that targeting the metabolic defects in this pathway might provide an opportunity for the develop ment of kidney cancer gene-specific therapies that are more durable and more effective than existing treatments.
the current targeted therapies for clear cell carcinoma have focused on targeting the genes that are transcriptionally upregulated by HiFs such as those coding for veGF, veGF receptors, the PDGF receptor and the serine-threonine protein kinase mammalian target of rapamycin (mtor)-HiF pathway. while most of these agents induce responses in patients with advanced kidney cancer, the responses are usually partial and most patients eventually experience progression. the fundamental metabolic nature of these cancer genes might be the achilles' heel that can be exploited to develop moredurable and more-effective forms of therapy. Here we describe the genes that have been identified in clear cell and non-clearcell kidney cancers, their involvement in cell metabolism pathways, and how they might be targeted to provide future therapies.
VHL
Positional cloning was used in patients with von Hippel-lindau disease to identify the VHL gene locus on the short arm of chromo some 3.
6-12 von Hippel-lindau disease is a hereditary cancer syndrome; affected individuals are at risk for the development of renal cysts and clear cell kidney cancer. Germline mutations of the VHL gene (intragenic, deletions or splicing defects) have been found in almost all families with von Hippel-lindau disease, 13 and somatic inactivation of VHL by methylation or mutation has been reported in up to 91% of patients with sporadic clear cell renal carcinoma. [14] [15] [16] [17] [18] [19] the vHl protein forms a complex with elongin B, elongin C, and cullin 2, 19 which targets HiFs for ubiquitin-mediated degrada tion (Figure 2a) . [20] [21] [22] this process is oxygen-dependent. During normoxia, HiF-α is hydroxylated on a critical proline residue by HiF prolyl hydroxylase (PHD); this process requires molecular oxygen, 2-oxoglutarate, ascorbate and Fe 2+ as co factors, which facilitate HiF-α binding to the vHl protein (pvHl), and proteasomal degrada tion by the e3 ubiquitin ligase complex. under hypoxic conditions, PHD cannot hydroxylate HiF-α; the pvHlelonginC-elonginB-cullin2 complex does not bind HiF-α, which, therefore, accumulates. 21, 22 similarly, when the VHL gene is mutated, mutant pvHl can no longer bind to HiF-α resulting in HiF overaccumulation (Figure 2b ). although considerable overlap opinion The genetic basis of kidney cancer: a metabolic disease
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Abstract | Kidney cancer is not a single disease but comprises a number of different types of cancer that occur in the kidney, each caused by a different gene with a different histology and clinical course that responds differently to therapy. Each of the seven known kidney cancer genes, VHL, MET, FLCN, TSC1, TSC2, FH and SDH, is involved in pathways that respond to metabolic stress or nutrient stimulation. The VHL protein is a component of the oxygen and iron sensing pathway that regulates hypoxiainducible factor (HIF) levels in the cell. HGF-MET signaling affects the LKB1-AMPK energy sensing cascade. The FLCN-FNIP1-FNIP2 complex binds AMPK and, therefore, might interact with the cellular energy and nutrient sensing pathways AMPK-TSC1/2-mTOR and PI3K-Akt-mTOR. TSC1-TSC2 is downstream of AMPK and negatively regulates mTOR in response to cellular energy deficit. FH and SDH have a central role in the mitochondrial tricarboxylic acid cycle, which is coupled to energy production through oxidative phosphorylation. Mutations in each of these kidney cancer genes result in dysregulation of metabolic pathways involved in oxygen, iron, energy or nutrient sensing, suggesting that kidney cancer is a disease of cell metabolism. Targeting the fundamental metabolic abnormalities in kidney cancer provides a unique opportunity for the development of more-effective forms of therapy for this disease.
exists in the genes that are transcriptionally regulated by HiF1-α and HiF2-α, in vitro and in vivo studies have indicated that HiF2-α is the critical HiF for tumorigenesis in clear cell kidney cancer. [23] [24] [25] Clear cell kidney cancers (with or without VHL mutation) that express both HiF1-α and HiF2-α exhibit enhanced signaling via the mitogen-activated protein kinase (maPK) and mtor pathways, whereas clear cell tumors that express only HiF2-α have elevated activity of the oncogene c-myc. 26 if HiF2-α is the critical pathway for kidney cancer tumorigenesis, targeting the HiF2-α pathway is likely to be more successful than solely targeting the HiF1-α pathway. efforts are currently underway to identify agents that down regulate HiF2-α-induced gene expression. in this regard, investigators at our institution have developed a cell-based reporter assay for screening of inhibitors of HiF2-α-induced gene expression to identify potential therapautic agents for VHL-deficient clear cell kidney cancer.
an increased understanding of vHl signaling has provided the foundation for the development of therapeutic approaches that target this pathway in patients with advanced clear cell kidney cancer. a number of drugs have recently been approved by the FDa that target either the downstream targets of HiF activity (such as the veGF receptor) or inhibit mtorC1, which provides trans lational control of HiF1-α. 27 these agents are discussed in detail elsewhere. 28 Briefly, bevacizumab is an antibody that targets veGF. sorafenib is a small molecule multikinase inhibitor that targets the veGF and PDGF receptors and the raf pathway. 29 sunitinib also inhibits veGF and PDGF receptors, and is most frequently used as a first-line agent in patients with advanced clear cell kidney cancer. 30 axitinib and pazopanib are recently developed selective inhibitors of the veGF receptors. 31, 32 Pazopanib has been approved by the FDa for treatment of metastatic kidney cancer, while axitinib is currently being evaluated in phase iii randomized trials. early clinical experience with these selective veGF receptor antagonists suggests that these agents might be better tolerated than sunitinib and sorafenib without compromising efficacy; if these observations are confirmed in phase iii randomized trials, selective veGF receptor antagonists are likely to be increasingly used as first-line agents in patients with advanced clear cell kidney cancer.
temsirolimus and everolimus inhibit mtor complex 1 (mtorC1). temsirolimus has been shown to prolong survival, compared with interferon, in patients with previously untreated kidney cancer with highrisk features. in patients who have progressed while on sunitinib or sorafenib, everolimus is associated with a modest prolongation of progression-free survival compared to placebo, and this agent is a reasonable second-line option in patients with advanced kidney cancer who have progressed on front-line therapy that targets the veGF pathway. most therapeutic agents currently approved to treat clear cell kidney cancer target selected downstream components of the HiF pathway including veGF and the veGF and PDGF receptors. the responses to these agents observed in patients with advanced clear cell kidney cancer is proof of principle that targeting the vHl-HiF pathway can induce tumor regression in humans. However, these agents target only a small proportion of the downstream genes regulated by HiFs. an approach to target HiF transcriptional activity or translation of HiFs themselves-that is, to affect all the genes regulated by HiFs-could potentially provide more-effective therapy. topotecan and TSC2 share the common feature that each is involved in oxygen, iron, energy or nutrient sensing pathways. 93 Thus, kidney cancer is fundamentally a metabolic disease. VHL targets HIF1-α and HIF2-α for ubiquitin-mediated degradation through an oxygen and iron sensing mechanism. HGF-MET signaling induces LKB1 phosphorylation via the Raf pathway, uncoupling AMPK energy sensing control of mTOR. The FLCN-FNIP1-FNIP2 complex binds AMPK, the primary energy sensor in the cell, and FLCN is phosphorylated by a rapamycinsensitive kinase (for example, mTORC1). TSC1-TSC2 is phosphorylated by the LKB1-AMPK cascade and helps mediate the cell's response to energy and nutrient sensing. FH and SDH are tricarboxylic acid cycle enzymes. Inactivation of FH or SDH impairs PHD function and represents a VHL-independent mechanism for dysregulation of HIF degradation. Increased HIF levels lead to increased transcription of a number of downstream genes such as GLUT1, which enables transport of glucose for ATP production, VEGF, which increases tumor vascularity, PDGF, which induces the growth of paracrine supporting structures, and TGF, which induces autocrine tumor growth. Abbreviations: Akt, proto-oncogene c-Akt; AMPK, 5'-AMP-activated protein kinase; FH, fumarate hydratase; FLCN, folliculin; FNIP , folliculin interacting protein; GLUT1, glucose transporter type 1; HGF, hepatocyte growth factor; HIF, hypoxia-inducible factor; LKB1, serinethreonine protein kinase 11; MET, hepatocyte growth factor receptor; mTOR, serine-threonine protein kinase mammalian target of rapamycin; PDGF, platelet-derived growth factor; PHD, HIF prolyl hydroxylase; PI3K, phosphatidylinositol 3-kinase; PTEN, phosphatase and tensin homolog; Rheb, GTP-binding protein Rheb; SDH, succinate dehydrogenase; TGF, transforming growth factor; TSC, tuberous sclerosis complex; VEGF, vascular endothelial growth factor; VHL, von Hippel-Lindau disease tumor suppressor. Permission obtained from Annual Reviews © Linehan, W. M. Ann. Rev. Med. 10, 329-343 (2010). p e r s p e C T i v e s is a topoisomerase 1 inhibitor that represses HiF1-α-dependent transcription. 33, 34 this agent is currently under evaluation in a phase i clinical trial in patients whose tumors express HiF1-α. 35 a number of groups are currently screening for agents that target transcription of HiF2-α trans criptionally regulated genes. 36 mtor is part of two distinct signaling complexes. the rapamycin-sensitive complex mtorC1 regulates cell growth and protein synthesis in response to growth factor stimulation by phosphorylating s6 kinase and the eukaryotic translation initiation factor 4e-binding protein 1 (4e-BP1) to modulate key regulators of messenger rna (mrna) translation. the rapamycininsensitive complex mtorC2 regulates actin cytoskeleton organization through phosphorylation of protein kinase Cα and also phosphorylates the serine-threonine protein kinase akt at s473 to activate the akt-mtorC1 pathway. the mtorC1 inhibitor temsirolimus and other 'rapalogs' suppress tumor growth in VHL-deficient clear cell kidney cancers via inhibition of HiF1-α translation. 37 most VHL-deficient tumors, however, express both HiF1-α and HiF2-α. 26 Knockout experiments have revealed that HiF1-α translation is dependent on mtorC1 signaling, whereas HiF2-α is downstream of the mtorC2 pathway. 38 new agents that target both the mtorC1 and mtorC2 pathways have the potential to downregulate both HiF1-α and HiF2-α in clear cell kidney cancers and could provide greater antitumor activity than temsirolimus and everolimus, which primarily target the mtorC1 pathway. aZD8055, an agent that inhibits both the mtorC1 and mtorC2 pathways, has been shown to have potent anti-tumor activity in both in vitro and in vivo model systems 39 and clinical trials evaluating the effectiveness of this agent are anticipated soon.
the development of other strategies that decrease translation of HiFs might also have significant potential for patients with advanced kidney cancer. the presence of an iron responsive element in the 5' untranslated region of HIF2-α mrna suggests that components of the iron metab olism pathway might be exploited to this end. 40 Cytoplasmic aconitate hydratase (iron regulatory protein 1; irP1) is an iron sensing protein involved in maintaining iron homeostasis. irP1 binds to the iron responsive elements of HIF2-a mrna and inhibits its translation. 41 ,42 overexpression of irP1 suppresses growth of lung tumor xenografts, 43 which has prompted the search for small molecules that could decrease HIF2-α translation by enhancing the binding of irP1 to the 5' untranslated region of its mrna. 44 identification of agents that enhance the binding of irP1 to the iron responsive element in the 5' untranslated region of HIF2-α mrna or mimic irP1 activity could provide a novel targeted approach to therapy.
turcotte et al. 45 have utilized a novel approach to identify agents that target the vHl pathway. they performed a synthetic lethal screen in a set of VHL-negative versus VHL-positive clear cell kidney cancer cell lines and identified stF-62247, a cytotoxic agent that inhibits tumor growth. stF-62247 selectively induced toxicity in VHL -/-cells in a HiF-independent fashion and was found to induce autophagy. this agent had activity both in vitro and in vivo, suggesting possible therapeutic potential for stF-62247 or a related agent in patients with advanced kidney cancer. By targeting autophagy, a central component of the cell's response to nutrient and energy deprivation, turcotte and colleagues have developed a new paradigm for cancer therapy. many chemotherapeutic and targeted tyrosine kinase approaches are limited by their toxic effects on non-tumor cells. However, targeting autophagy affected only the VHL -/-cells, whereas cells with a wild-type copy of the VHL gene were not affected. 45 this approach, targeting the fundamental metabolic defect in the cell, has the potential to provide a less-toxic and more-effective form of therapy for patients with this disease.
MET the proto-oncogene MET (hepatocyte growth factor receptor) was identified as the gene for hereditary papillary renal carcinoma by genetic linkage analysis in families with this inherited renal cancer syndrome. MET encodes the cell surface receptor for hepatocyte growth factor (HGF), which is involved in mitogenesis, morphogenesis and 
Figure 2 | Abnormal VHL activity leads to HIF accumulation. a | The VHL E3 ubiquitin ligase complex targets HIFs for ubiquitin-mediated degradation. 22 This process is mediated by PHD and an essential cofactor, 2-OG. When the cell is hypoxic or iron levels are low, the VHL complex cannot target and degrade HIF and HIF overaccumulates, driving the transcription of a number of genes important in cancer, such as VEGF, PDGF, and GLUT1. 22, 94 b | When the VHL gene is mutated, as in clear cell kidney cancer, the complex cannot target and degrade HIF. HIF2-α is thought to be a critical pathway for VHL-deficient clear cell kidney tumorigenesis. 23, 25 Abbreviations: 2-OG, 2-oxoglutarate; CUL2, cullin 2; E2, ubiquitinconjugating enzyme; GLUT1, glucose transporter type 1; HIF, hypoxia-inducible factor; ODD, oxygen-dependent degradation domain; PDGF, plateletderived growth factor; PHD, HIF prolyl hydroxylase; Rbx1, ring box protein 1, which has a role in ubiquitination by forming a heterodimer with CUL2; UB, ubiquitin; VEGF, vascular endothelial growth factor; VHL, von Hippel-Lindau disease tumor suppressor. 46 activating mutations in the tyrosine kinase domain of MET have been detected in the germline of affected patients and in a subset of sporadic type 1 papillary kidney cancers. 47, 48 the histological patterns of hereditary and sporadic type 1 papillary kidney tumors with MET mutations share a distinct morphological phenotype consisting of papillary or tubulopapillary architecture with slender short papillae containing delicate fibrovascular cores lined by small cells with low-grade basophilic nuclei and scant amphophilic cytoplasm. 49 one effect of growth-factor-dependent activation of the phosphatidylinositol 3-kinase (Pi3K) signaling pathway is increased cell surface expression of nutrient transporters, which increases uptake of amino acids, glucose and other nutrients. 50 response to an agent with activity against MET might be seen in tumors that are characterized by a mutation in the tyrosine kinase domain of MET; such an agent might also have activity in tumors that have MET amplification. whether an agent such as foretinib would have activity against kidney tumors that are caused by mutation of other genes such as TSC1 or TSC2 is not known.
TSC1-TSC2
the tuberous sclerosis genes TSC1 and TSC2 are also involved in the amPKmtor nutrient and energy sensing pathway (Figure 1 ). Germline mutations in one or other of these genes have been identified in patients with tuberous sclerosis complex, an autosomal dominant disorder associated with the development of cutaneous angiofibromas, pulmonary lymphangiomyomatosis and renal tumors. 51 angiomyolipoma is the most common renal tumor found in affected individuals; however, other tumor types have been reported, including clear cell renal carcinoma.
52
TSC1 encodes hamartin and TSC2 encodes tuberin, which form a hetero dimer that acts as a GtPase-activating protein toward rheb, a ras-family GtPase that activates mtorC1. GtPase activity of the tsC1-tsC2 complex on rheb results in inhibition of mtor activity. TSC1-deficient and TSC2-deficient tumors exhibit increased phosphorylation of p70s6 kinase, s6 ribosomal protein and 4e-BP1, downstream effectors of mtorC1 activation, and readouts for initiation of mrna translation and protein synthesis. 51 lack of tsC1-tsC2 inhibition of mtor would presumably also result in HiF accumula tion through increased HIF mrna translation by activated mtorC1.
sirolimus has been demonstrated to cause regression of renal angiomyolipomas in patients with tuberous sclerosis complex. sirolimus forms a complex with FK binding protein 12 and inhibits mtorC1 signaling. 48 although most kidney tumors that regressed on therapy tended to increase in volume after the treatment was stopped, this study provided the foundation for a molecular therapeutic approach to the treatment of renal tumors associated with the TSC1-TSC2 pathway. a number of trials evaluating the role of sirolimus in patients with tuberous sclerosis complex are currently in progress. when the role of this agent in patients with tuberous sclerosis complex has been defined, future trials that combine this agent with other drugs that target this pathway will be possible.
FLCN
Genetic linkage analysis in patients with Birt-Hogg-Dubé syndrome identified FLCN, a novel gene on the short arm of chromosome 17, as the causal gene. 53, 54 Patients with Birt-Hogg-Dubé syndrome are at risk for the development of benign cutaneous tumors (fibrofolliculomas), 55 pulmonary cysts 55 and chromophobe kidney tumors (Figure 3) . 56 these tumors can be bilateral, multifocal and can metastasize. 57 
p e r s p e C T i v e s
Folliculin is also involved in the amPKmtor pathway; it forms a complex with folli culin interacting proteins 1 and 2 (FniP1 and FniP2), which binds the γ-subunit of amPK (Figure 4a) . [62] [63] [64] the functional significance of this interaction and the mechanism by which folliculin may regulate amPK-mtor signaling is currently unknown but is under intense investigation by a number of laboratories. one approach to understanding folli culin function is through the study of in vivo animal models in which FLCN is inactivated. Both the mtorC1 and mtorC2 pathways were activated in the kidney tumors of a FLCN knockout mouse (Figure 4b) . 65 these findings suggest that targeting both the mtorC1 and mtorC2 pathways might show promise for patients with kidney cancers associated with Birt-Hogg-Dubé syndrome.
the FLCN gene has been selectively inactivated in the kidneys of a murine model; affected mice developed enlarged polycystic kidneys and died from renal failure by 3 weeks of age. 66, 67 FLCN knockout mice treated with rapamycin had smaller, lesscystic kidneys than untreated FLCN knockout mice and a longer median survival time. 66 the results in this in vivo model of Birt-Hogg-Dubé syndrome would suggest that rapamycin analogs such as sirolimus might be potential therapeutic agents against renal tumors.
Tricarboxylic acid cycle genes
the tricarboxylic acid cycle is part of a metabolic pathway coupled to mitochondrial oxidative phosphorylation that converts nutrients to energy in aerobic cells. the fumarate hydratase (FH) and succinate dehydrogenase (SDH) genes encode mitochondrial tricarboxylic acid cycle enzymes that have an essential role in energy production by catalyzing the conversion of fumarate to malate and succinate to fumarate, respectively. individuals who harbor germline mutations in either of these tricarboxylic acid cycle enzymes have an increased risk of developing renal tumors. f o C u s o n k i d n e y C A n C e r www.nature.com/nrurol over 90% of north american individuals with HlrCC. [70] [71] [72] inhibition of FH leads to increased levels of fumarate, which inhibit the activity of PHD, resulting in HiF-α accumula tion and transcriptional upregula tion of HiF target genes, thereby contributing to the highly aggressive nature of HlrCC-associated renal tumors. 73 the inhibition of PHD by the increased levels of fumarate provides a vHl-independent mechanism for dysregulation of HiF degradation in FH-deficient HlrCC-associated kidney cancers (Figure 6 ).
FH-deficient kidney cancer cell lines are glucose-dependent 74, 75 and have significantly impaired oxidative phosphoryla tion. 74, 76 sudarshan et al. 75 have demonstrated that the glucose-mediated generation of cellular reactive oxygen species in an FH-deficient kidney cancer cell line results in stabilization of HiF1-α. the impaired oxidative phosphorylation in FH-deficient kidney cancer results in a nearly total dependence on glyco lysis for energy production. Downstream HiF1-α genes such as VEGF and GLUT1 (which encodes the glucose transporter type 1) would, therefore, be critically important to these cancer cells for increasing vasculature and glucose transport. tumor vasculature and glucose transport could be the achilles' heel for these aggressive cancers, which are so dependent on glucose transport for energy production. whereas targeting the vasculature in patients with advanced vHl-deficient clear cell kidney cancer has resulted in only modest success, targeting the vasculature in a cancer whose metabolism is so completely dependent on glucose transport for energy production could provide a powerful and effective approach to therapy.
SDH
Germline mutations in three of the four succinate dehydrogenase genes (SDHB, SDHC, and SDHD) have been associated with familial paraganglioma and familial pheochromocytoma. 77, 78 individuals with these hereditary disorders are at risk for the develop ment of extra-adrenal paraganglioma or pheochromocytoma and carotid body tumors. early-onset renal tumors have been found to develop in individuals with germline SDHB mutations. [78] [79] [80] [81] [82] in preclinical models, increased succinate has been shown to inhibit PHD and affect HiF stability. 73 inactivation of succinate dehydrogenase would be expected to severely impair oxidative phosphorylation and lead to glucose dependence of sDH-deficient kidney tumors (Figure 6 ). sDH-deficient kidney tumors are likely to be as sensitive to glucose as FH-deficient tumors and targeting the vasculature or glucose transport in these tumors could provide a novel approach to disrupt the fundamental metabolic machinery of these aggressive cancers.
A metabolic disease mutations in each of the seven known kidney cancer genes lead to the dysregulation of at least one metabolic pathway that is mediated by oxygen, iron, energy or nutrient sensing, which suggests that kidney cancer is a disease of dysregulated cellular metabolism. the common end point of VHL, FH and SDH mutations is the stabiliza tion of HiFs through inactivation of PHD, which drives the transcriptional activa tion of genes that support tumor growth, neovascularization, invasion and metastasis. HiF translation is upregulated by activation of the mtor pathway as a consequence of its dysregulation by TSC1-TSC2 or FLCN mutations, or oncogenic HGF-met signaling through ras-erk1/2-mek1/2-p90 rsK phosphorylation of lKB1. targeting HiFs and their downstream genes has provided a first-line therapeutic approach to vHldeficient kidney tumors that can be applied to FH-deficient and sDH-deficient tumors as well.
Progress has been made in this approach to targeted therapy for kidney cancer during the past few years. in this time, six novel agents focusing on the vHl pathway have been approved for the treatment of patients with advanced kidney cancer. However, even the most commonly used agent, sunitinib, has a partial response rate of only 31% and a progression-free survival advantage over interferon therapy of 6 months (11 versus 5 months). 83 most patients with advanced kidney cancer treated with targeted agents eventually experience progression and very few have long-term complete responses. thus, a need exists for novel therapeutic approaches for this tumor type. one report describing a novel agent, stF-62247, which targets autophagy selectively in VHLdeficient clear cell kidney cancer is an excellent example of an innovative approach to therapy for vHl-deficient tumors and highlights the role of metabolic defects in this cancer. Oxidative phosphorylation is impaired by the loss of FH and the cells depend on glycolysis for energy production. 74, 85 (2) SDH deficiency is also associated with familial renal carcinoma. Increased levels of succinate also inhibit PHD and a similar mechanism of tumorigenesis is likely to exist in SDH-associated kidney cancer. 74 Abbreviations: 2-OG, 2-oxoglutarate; FH, fumarate hydratase; GLUT1, glucose transporter type 1; HIF, hypoxia-inducible factor; HLRCC, hereditary leiomyomatosis renal cell carcinoma; PHD, HIF prolyl hydroxylase; SDH, succinate dehydrogenase; VEGF, vascular endothelial growth factor; VHL, von Hippel-Lindau protein.
p e r s p e C T i v e s researchers could potentially spend the next decade performing clinical trials evaluating different combinations of tyrosine kinase inhibitors that target a limited number of downstream HiF pathway genes, with only minimal incremental improvement in outcome. thinking about kidney cancer as a metabolic disease and targeting the kidney cancer gene metabolic abnormali ties provides a potentially different paradigm for the therapy of this disease. as we learn more about the metabolic basis of kidney cancer and start to think about these cancers in a different way, we may find that the oxidative phosphorylation status of an individual tumor rivals in importance the activation status of downstream HiF targets for guiding rational targeted therapeutic approaches.
the two best examples of a metabolic basis for kidney cancer are FH-deficient and sDH-deficient kidney cancers, which highlight the 'warburg effect' in cancer (whereby cancer cells generate energy by glycolysis instead of mitochondrial oxidative phosphorylation, even in normoxic conditions). 84 the FH-deficient uoK262 kidney cancer cell line, established from an HlrCC-associated renal tumor, has severely impaired oxidative phosphorylation and is dependent on glycolysis for energy production. this observation is supported by ultrastructural analysis of uoK262 kidney cancer cells, which revealed abnormal mitochondria with significantly distorted cristae. 74 these FH-deficient tumor cells have significantly increased glucose transport and are extremely dependent on glucose for growth. 74 FH-deficient HlrCC tumors in patients express high levels of the glucose transporter, Glut1, and these tumors characteristically demonstrate high uptake of 18 F-fluorodeoxyglucose on Pet. 73, 74 targeting the vasculature and impairing glucose transport in a glucose-addicted tumor could provide a new paradigm for treatment of these lethal malignancies. interestingly, although the genetic basis of sporadic chromophobe renal carcinoma and oncocytomas is not known, ultrastructural analysis of these renal neoplasms reveals abnormal mitochondria with altered cristae, which are also suggestive of compromised mitochondrial function. 85 the mitochondrial defects shared by FH-deficient tumors, sporadic chromophobe renal tumors and renal onco cytomas might suggest a common approach to therapy for these tumor types.
treatment with inhibitors of mtor activity has been applied to tsC2-deficient tumors and might show promise for FlCndeficient tumors in the future. Furthermore, there has been renewed interest in agents such as metformin that activate amPK, which in turn downregulates mtor activity, as a potential treatment for kidney cancer. metformin use has been associated with decreased cancer mortality in patients with type ii diabetes 86, 87 and has been shown to block tumor growth in combination with chemotherapeutic agents in preclinical in vitro and in vivo models of cancer. 88, 89 although metformin is taken by patients with type ii diabetes worldwide and is a relatively nontoxic agent, certain risks, such as an increase in cardiovascular mortality, are associated with its long-term use. 86 However, if such agents were found to be effective components of a targeted therapeutic approach, the benefits of these drugs would seem to far outweigh the potential risks.
if we think about the factors known to increase the incidence of kidney cancer, it is not surprising that kidney cancer is fundamentally a metabolic disease; numerous studies have shown a significant association between Bmi, obesity and the development of kidney cancer. 90 we have learned much from our study of the metabolic basis for kidney cancer, which should enable us to predict the pathways that are likely to be involved in particular histologic types of kidney cancer, leading to the design of moreeffective therapies. although the genetic basis of rarer types of kidney cancer such as medullary renal carcinoma is not known, it is likely that the origin of this cancer is associated with hypoxia. medullary renal carcinoma is an aggressive form of kidney cancer seen almost exclusively in patients who are affected with sickle cell disease or trait. 91 sickle cell disease can be associated with a number of nephropathies, including microangiopathy. 92 it would not be surprising to find medullary renal carcinoma developing from a hypoxic area of renal parenchyma, which might show elevated levels of HiFs and might respond to targeted anti-HiF therapies.
Conclusions
Kidney cancer is fundamentally a metabolic disease; each of the inherited kidney cancer syndromes caused by germline mutations in the kidney cancer genes identified to date represent disorders in oxygen, iron, nutrient or energy sensing (Figure 1) . identification of the genes for kidney cancer has provided the foundation for development of targeted approaches to therapy for patients with these disorders. while considerable progress has been made in the development of novel therapeutic approaches for patients with kidney cancer, there remains a significant opportunity for targeting the common metabolic defects in these cancer gene pathways. the 30-35% response rates observed in patients with advanced clear cell kidney cancer treated with agents such as sunitinib are very encouraging proof of principle that targeting kidney cancer gene pathways can have an effect on this disease. targeting metabolic abnormalities such as autophagy, glucose transport and energy sensing provides a new paradigm that will hopefully provide more-effective forms of therapy for patients with kidney cancer. 
